Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of follicular lymphoma, according to the Revised European American Lymphoma/World Health Organization \[REAL/WHO\] classification
Documented CD40+ follicular lymphoma
Measurable lesion
Refractory to rituximab
Prior treatment with at least 1 chemotherapeutic regimen
18 years or older
WHO Performance Status grade 0, 1, or 2
Life expectancy \> 3 months
Obtained written informed consent
You may not be if
Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma (i.e. DLBCL)
History of another primary malignancy that is currently clinically significant or currently requires active intervention
Prior allogeneic stem cell transplantation
Prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration
Impaired cardiac function or clinically significant cardiac disease
History of acute or chronic pancreatitis, surgery of the pancreas, or any risk factors that may increase the risk of pancreatitis
History of an active infection (viral, bacterial, or fungal) requiring systemic therapy within 28 days before study treatment.
Known diagnosis of human immunodeficiency virus (HIV) infection
Evidence of previous hepatitis viral infection such as hepatitis B or hepatitis C
Ongoing corticosteroid use (\>10 mg/day prednisone or equivalent)
